BiomX (PHGE) Other Non-Current Liabilities (2018 - 2026)
BiomX (PHGE) posted Other Non-Current Liabilities of $1.7 million for Q1 2026, up 138.67% sequentially from $706000.0 in Q4 2025, and up 2032.91% YoY from $79000.0 in Q1 2025.
BiomX (PHGE) Other Non-Current Liabilities (2018 - 2026) Analysis & Trends
BiomX has reported Other Non-Current Liabilities for 9 years, with the latest figure at $1.7 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 2032.91% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 2032.91% YoY) and the FY2025 annual result came in at $706000.0, down 69.13% from the prior year.
- Other Non-Current Liabilities grew to $1.7 million in Q1 2026 per PHGE's latest filing, from $706000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $2.3 million in Q4 2024 and troughed at $34000.0 in Q3 2025.
- A 5-year average of $418000.0 and a median of $189000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Liabilities tumbled 78.88% in 2025, then surged 2032.91% in 2026.
- Over 5 years, Other Non-Current Liabilities stood at $188000.0 in 2022, then declined by 17.55% to $155000.0 in 2023, then surged by 1375.48% to $2.3 million in 2024, then plunged by 69.13% to $706000.0 in 2025, then jumped by 138.67% to $1.7 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $1.7 million, $706000.0, and $34000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | BiomX | 361,408.40 | -806,591.60 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.69 Mn |
| Dec 31, 2025 | 706,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 80,000.00 |
| Mar 31, 2025 | 79,000.00 |
| Dec 31, 2024 | 2.29 Mn |
| Sep 30, 2024 | 161,000.00 |
| Jun 30, 2024 | 153,000.00 |
| Dec 31, 2023 | 155,000.00 |
| Sep 30, 2023 | 148,000.00 |
| Jun 30, 2023 | 190,000.00 |
| Mar 31, 2023 | 192,000.00 |
| Dec 31, 2022 | 188,000.00 |
| Sep 30, 2022 | 206,000.00 |
| Jun 30, 2022 | 209,000.00 |
| Mar 31, 2022 | 215,000.00 |
| Dec 31, 2021 | 215,000.00 |
| Sep 30, 2021 | 420,000.00 |
| Jun 30, 2021 | 419,000.00 |
| Mar 31, 2021 | 572,000.00 |